01
Dec
2008
Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Antibody, X - Reagent
BAC (Netherlands) early-stage company focused on developing purification ligands and immobilized purification products, closed a $1.9M Series B financing. Participants include Unilever Ventures, FF&P Private Equity, Fleming Family & Partners.